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background: Stem cell therapy using cardiac stem cells (CSCs) is receiving increasing attention recently. Most studies use autologous CSCs, with 
the timing constraints this imposes. The use of allogeneic CSCs would allow for early administration. We undertook this study to assess the safety of 
early delivery and the possible influence of the timing of allogeneic porcine CSCs (pCSCs) delivery after acute myocardial infarction (AMI) on cardiac 
function.
Methods: A closed chest model of AMI was created by a 90 minutes balloon occlusion of the mid-LAD in female domestic swine. Surviving animals 
were allocated to receive an intracoronary (IC) injection of 25x106 pCSCs either two hours (n=5, Group 1) or 7 days (n=5, Group 2) after reperfusion. 
IC injection of vehicle on day 7 was performed as control (n=5, Group 3). Coronary flow was assessed immediately after injection and 10 weeks post-
AMI. Cardiac Magnetic Resonance (MR) studies were performed for morphological and functional assessment one and 10 weeks after infarction, 
determining Ejection Fraction (EF), End Diastolic Volume (EDV), End Systolic Volume (ESV) and infarct size.
results: Injection of pCSCs was successful in all animals at both 0 and 7 days after AMI, in absence of major adverse cardiac events. Post injection 
coronary flow was scored as TIMI 3 in all animals but one belonging to group 1. TIMI scores at 10 weeks post-AMI were significantly (p=0.041, 
Kruskall Wallis test) lower in the control group (median score = 2). No significant differences in MR-derived cardiac function parameters or infarct 
sizes were seen in any case, but a trend towards better function and limited chamber dilatation at 10 weeks was seen in the treated groups, with 
the better functional results belonging to Group 2 (EF was 44.88%±6.24%, 42.58%±8.80% and 42.60%±11.91%; EDV was 82.33mL±12.21mL, 
91.17mL±10.34mL and 100.30mL±20.53mL and ESV was 45.41mL±8.38mL, 52.42mL ±10.07mL and 59.00mL±22.72mL, respectively in Group 2, 
Group 1 and Group 3)
conclusion: The administration of 25x106 allogeneic pCSCs at 2 hours or 7 days after AMI appears to be safe, and could alleviate myocardial 
dysfunction in this experimental setting, especially when performed 7 days after infarction.
